Johnson & Johnson Wins U.S. Approval for Expanded Remicade Use
This article is for subscribers only.
Johnson & Johnson won U.S. approval for an expanded use of Remicade to treat children with a chronic inflammatory bowel disease who don’t respond to traditional therapy.
The Food and Drug Administration cleared the medicine chemically known as infliximab for pediatric ulcerative colitis, the company said today in a statement.